HPV vaccine recommendations.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22371460.
- Also identified by DOI 10.1542/peds.2011-3865.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended that the quadrivalent human papillomavirus vaccine (Gardasil; Merck & Co, Inc, Whitehouse Station, NJ) be used routinely in males. The American Academy of Pediatrics has reviewed updated data provided by the Advisory Committee on Immunization Practices on vaccine efficacy, safety, and cost-effectiveness as well as programmatic considerations and supports this recommendation. This revised statement updates recommendations for human papillomavirus immunization of both males and females.
Medical subject headings
- Immunization Programs
- Papillomavirus Infections
- Papillomavirus Vaccines
- Practice Guidelines as Topic